Latest News

Aagami has been appointed for BD support, by an independent global Contract Research Organization (CRO) offering comprehensive non clinical GLP research services for regulatory submissions, worldwide.

Read more...

A UK based pharma company has appointed Aagami to look for strategic partnership relating to their branded generics laxative for treatment of chronic constipation and faecal impaction, for India market.

Read more...

A US biotechnology-based pharmaceutical company focused on the development and commercialization of novel cancer therapies has appointed Aagami to seek companies in South Korea who would like to in-license their novel therapeuic vaccine platform.

Read more...

Aagami CEO Dinesh Jain will visit Seoul in South Korea in December 2016, to attend the Korea Drug Development Fund Techfair 2016. He is a key speaker for the event.  He will also be meeting several Bio Pharma companies to promote strategic partnerships for Aagami's clients who are developing new assets and technologies.

Read more...

A Canada based past client of Aagami, has appointed Aagami for seeking licensing/do-development partnerships for their Phase 3 chemotherapy candidate, in South Korea, Taiwan, Turkey, Austalia and New Zealand.

Read more...